Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Open evidence library

Search the archive.

Current and older evidence is free during beta. Sign in for unlimited card access and full source downloads.

Matching cards
2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---IL---Disease

Specifically solves environmental pathogens---new research is key

Gerard A. Cangelosi 5, Prof of Environmental and Occupational Health Sciences and Adjunct Prof of Epidemiology and of Global Health at the University of Washington, PhD in Microbiology from UC Davis, Nancy E. Freitag, PhD, Prof in the Dept of Microbiology and Immunology at the University of Illinois Chicago School of Medicine, and Merry R. Buckley, Ph.D. in environmental microbiology at Michigan State University, “From Outside to Inside: Environmental Microorganisms as Human Pathogens,” http://academy.asm.org/index.php/environmental-microbiology-ecology-evolution/553-from-outside-to-inside-environmental-microorganisms-as-human-pathogens

The key difference between environmental pathogens and other human pathogens is their ability to survive and thrive outside the host. Their widespread occurrence in the environment makes them difficult to monitor and control. Inroads have been made to understand the persistence of these organisms in the environment, the reservoirs they inhabit, the ways they exchange virulence factors, and their diversity, but a great deal more research is needed. By grouping together phylogenetically diverse organisms under the umbrella of "environmental pathogens," it is hoped that the topic can gain the critical mass needed for sustained progress. ¶ Colloquium participants examined other research needs for the field, including the diagnostic and environmental technologies that will be necessary for taking the next steps. It was agreed that because of the complex nature of studying organisms that can exist in the environment and in human hosts, work in this area is best carried out in an interdisciplinary fashion with coordinated input from medical, molecular, and environmental microbiologists, specialists in host responses, epidemiologists, ecologists, environmental engineers, and public health experts. The development of improved diagnostic techniques is critical for accurate assessment of health risks and potential human or animal population impact associated with environmental pathogens.If the impacts of these diseases are to be effectively controlled, the techniques used to monitor and control infections by environmental pathogens—including interventions, exposure controls, drugs, and vaccines— require improvement. The processes surrounding drug and vaccine development must be tailored to the special problem of environmental pathogens, which often strike small numbers of individuals or individuals in less developed areas of the world and, therefore, offer less potential for drug development profit than more common diseases. A challenge exists, therefore, in meeting the need for targeted, specific interventions, including development of drugs and vaccines for infections by environmental agents, in the face of a lack of financial incentive for development of these tools.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---AT: Insurance Coverage Link Turn

Decreased per-unit price outweighs the increase in profits from more insured citizens

Peter Pitts 9, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, 7/16/9, “Government negotiations in drug prices are dangerous”, http://blogs.reuters.com/great-debate/2009/07/16/drug-price-negotiations-in-the-public-option-dangerous/

An important power of this “public option” has yet to receive much scrutiny, though. The secretary of Health and Human Services will be given the authority to “negotiate” prescription drug prices for the public option. This is a big deal. Government “negotiations” with private vendors almost always mean public officials simply dictating below-market prices. If that holds true in the public option, drug companies that want to participate in the program will be forced to deeply discount their meds. These negotiations might translate into cost-savings for patients up front. But the long term effect would be a stifling of pharmaceutical innovation, leading to fewer new breakthrough medicines and compromised patient care. How so? Developing a new pharmaceutical drug is incredibly expensive. The whole process –including the initial research stages, the countless in-lab experiments required to turn a promising chemical into a usable drug, and the slow, grinding navigation through the FDA’s notoriously difficult safety approval pathway — costs over a billion dollars and takes over a decade for the average drug. Forcing pharmaceutical makers to sell at artificially low prices for a substantial slice of their customer base would drastically reduce their revenues, and leave an increasingly small amount for financing the discovery of new drugs.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---AT: Insurance Coverage Link Turn

Increased demand has marginal effects on productive innovation---but large price shocks collapse innovation

David Dranove 14, Walter McNerney Distinguished Professor of Health Industry Management at Northwestern University's Kellogg School of Management, With Craig Garthwaite and Manuel Hermosilla, June 2014, “Pharmaceutical profits and the social value of innovation,” http://www.kellogg.northwestern.edu/faculty/garthwaite/htm/medicare_pharma_innovation.pdf

Our results are quite different when we examine whether the new products spurred by Part D provide innovative treatments or treatment pathways as measured by the absence of existing treatments for the same conditions and by FDA designations of novelty. We find no evidence that the passage of Part D caused the emergence of innovative products across these dimens\ons. The research activity following a demand shock is primarily for products targeting conditions with five or more treatments. For these products we estimate an implied elasticity of clinical trials to change in revenues of 3.3 – far closer to the estimates of the earlier literature. In addition, we see no evidence of an increase in products receiving FDA designations.

It could be that breakthroughs of these kinds take longer to develop than incremental innovations. This is particularly true if biotech firms have a cache of potential products that are marginal unprofitable before a small change in market demand and their immediate response to a shift in demand is to bring these products “off the shelf.” While there is no systematic method of calculating the time from basic science to human trials, we do note that we examine a relatively long window after the passage of Part D and that there are prominent examples of compounds being identified and reaching human trials in far less time. For example, the hepatitis C cure Solvaldi discussed earlier was primarily the result of the work of Michael Sofia at Pharmasset. Sofia joined the firm in 2005 and Sovaldi entered clinical trials five years later (Gounder, 2103). Similarly, Merck’s insomnia treatment Suvorexant moved from first concept to clinical trials in four to six years (Parker, 2013). While these provide only anecdotal evidence, they do demonstrate that the time period we consider after Part D is sufficient for some socially valuable products to reach market. That being said, we realize that we cannot rule out the possibility that over an even longer horizon more innovative products could enter clinical trials as a result of this marginal demand shock.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---Innovation Link

The aff causes political uncertainty and revenue decline for pharma companies---that causes them to cut new RnD programs

David Epstein 17, executive partner at Flagship Pioneering. March 17. “The next horizon of innovation for pharma” http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-next-horizon-of-innovation-for-pharma

You also have to look at the external environment and think about what could go wrong. We should always worry when there’s political change. For instance, when payors—which is the government in most parts of the world—come under economic pressure, changes in legislation could disrupt the innovation process. If all of a sudden investors had no hope of being able to take their companies public and make a good return, that money would dry up, as would innovation. If pharma companies saw prices fall so far that their margins came under huge pressure, they would cut costs and reduce R&D as well as other spending. Eventually there would be an industry shakeout, and it would correct itself, but you’d have several years or longer where things slowed down or paused, and that’s an ongoing risk.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---Innovation Link

Lower profit margins discourage investment in new treatments---economic models prove

RAND 08---RAND Health, a division of the RAND Corporation, is the nation's largest independent health policy research program, with a broad research portfolio that focuses on quality, costs and health services delivery, among other topics. 12/16/08, “Drug Cost Regulations Would Hurt Future Medical Innovation; Lower Copays a Better Option” https://www.rand.org/news/press/2008/12/16.html

Controlling prescription drug prices is one way to lower U.S. health costs, but it comes at a cost for future generations, according to a new RAND Corporation study.

While imposing European-style prescription drug price regulations in the United States would generate modest cost savings, it would impose a larger burden in the future by stifling medical innovation that can extend lives, according to two RAND Health studies published online by the journal Health Affairs.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---Innovation Link

Single payer kills medical innovation---cost incentives, rationing, and picking winners

The Economist 7---The economist is an award winning magazine. 4/16/07, “In the name of innovation” https://www.economist.com/blogs/freeexchange/2007/04/in_the_name_of_innovation

Since we have made that argument on this very blog, I feel compelled to defend it from those who misunderstand it.

First of all, the argument is not that government never innovates, nor even that it never provides services better than the private sector. It is much more subtle than that. The problem is that when the government picks a winner, there is a very good chance that they will pick the wrong one. It is fun to scan all the various government agencies involved in providing health care and choose a single example of one with a good medical records system, and then proclaim that as a benefit of government provision. But one could perform the same feat on lots of private systems, provided one gets to choose the outliers. Yes, European government planning produced GSM cell phones . . . but it also produced Minitel.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---Innovation Link

Single-Payer wrecks innovation---price controls, and service rationing---cross-country analysis proves

Glen Whitman 10, is an associate professor of economics at California State University, Northridge. Raymond Raad, M.D., M.P.H., is a resident in psychiatry at New York Presbyterian Hospital / Weill Cornell Medical Center. 1/6/10, “The Healing Power of Innovation” https://www.cato.org/publications/commentary/healing-power-innovation

Why does America outpace the rest of the world in medical innovation? It’s not our large population. The combined population of the E.U. and Switzerland exceeds the U.S. population by more than 50%.

Many characteristics of a country can affect innovation, including the patent system, tax code, medical culture, general business climate and quality of universities. But health care policy surely plays a major role. It seems likely that American medical innovation is driven largely by something often regarded as a defect: the fact that we spend so much money.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---Innovation UQ

Healthcare is entering an era of hyper-innovation.

Rebecca Torrence 21, covers healthcare technologies and the businesses innovating them as a staff writer at Fierce Healthcare, following a range of issues from cybersecurity and artificial intelligence to telehealth and remote patient monitoring; graduated from Duke University with a B.S. in neuroscience. 10-29-21, "Healthcare is in an era of 'hyper-innovation' as executives look to ramp up digital tech: survey," Fierce Healthcare,

Businesses around the world have entered an “era of hyper-innovation,” according to Citrix Systems—and the healthcare industry is accelerating into the future at an especially rapid pace.

When Citrix surveyed (PDF) 1,200 business leaders across six different industries, healthcare ranked near the top of the industries adopting new technologies and work models.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---Innovation UQ

Innovation is high despite costs.

Kelly Anderson 21, Executive Director, Health and Drug Policy, Global Innovation Policy Center. 10-12-2021, "Medical Innovation Happens Across America," No Publication,

America is where innovation thrives, and cutting-edge medicine is no exception. Right now, scientists are conducting more than 140,000 clinical trials across all 50 states to explore the potential of the therapeutics, vaccines, diagnostics, and cures we need to fight disease—from coronavirus to cancer.

There’s no question that life-changing, lifesaving solutions are on the way - as long as we keep the path from mind to market as smooth and obstacle-free as possible. Because, as the data shows, the path is already treacherous enough.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 1NC---Innovation Turn

Turns the case

Thomas Bollyky 16, senior fellow for global health, economics, and development at the Council on Foreign Relations. Adjunct professor of law at Georgetown. With Steve Davis. 5/31/16, “Back to the Future of Global Health Security” https://www.cfr.org/expert-brief/back-future-global-health-security

Growing populations, rising global temperatures, urbanization, and easier trade and travel are all changing the world in ways conducive to the spread of infectious disease. The recent Ebola and Zika outbreaks have dominated news headlines and their toll has been terrible, but a more lethal infectious disease could do far worse harm.

“For infectious diseases, you cannot trust the past when planning for the future,” warned Margaret Chan, the head of the World Health Organization (WHO), at the World Health Assembly last week in Geneva. “What we are seeing,” she said, is “a dramatic resurgence of the threat from emerging and reemerging infectious diseases. The world is not prepared to cope.”

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 1NC---Innovation Turn

The plan decimates medical innovation globally

Ryan Huber 17, PhD, Executive Editor of Arc digital magazine. 3/29/17, “U.S. Health Care Reality Check #1: Pharmaceutical Innovation” https://arcdigital.media/u-s-health-care-reality-check-1-pharmaceutical-innovation-574241fb80ba

That is, despite the many regulations and laws aimed at consumer protection and safety that do exist in the United States, our health care market is relatively freer and more dynamic than those of other developed countries. This leads to a high rate of medical and pharmaceutical innovation that ends up benefiting the rest of the world, particularly other rich countries, in a similar way that NATO nations, for example, benefit from close military alliance with the United States. In short and somewhat reductive terms: we spend more money so everyone else can be healthier.

But this doesn’t make total sense at first. If the United States is developing more innovative medicines, devices, and procedures than every other advanced economy, why aren’t we making money by selling these medical innovations to others for a hefty profit? Why aren’t there many more billions of dollars of revenue coming into the United States Treasury because of our status as a medical innovator?

2023 Northwestern Affirmative
Off › Part E CP › Avoids Taxes DAs---2NC

Plan imposes an economy-wide tax of 91.9 billion dollars – our 1NC Hacker evidence says the plan costs 1.4 trillion – means the CP’s tax is 6.5% of the plan’s.

Lewin Group 8 – The Lewin Group, health care consulting firm, prepared for the Economic Policy Institute (“Cost Impact Analysis For The ‘Health Care For America’ Proposal,” February 15th, http://www.sharedprosperity.org/hcfa/lewin.pdf)

Health Care for America would be financed through premiums and the 6 percent payroll tax on employers. Employers who find the cost of the payroll tax cheaper than providing private coverage would opt to pay the tax. This would generate about $91.9 billion in revenue for the Plan. Employee premiums would generate about $49.3 billion in revenues and the premiums, net of subsidies, from those who enroll privately in Health Care for America would bring in about $31 billion. People below the federal poverty level are not required to pay any premiums and premiums are phased in through 400 percent of the FPL.

2023 Northwestern Affirmative
Off › Part E CP › Avoids Taxes DAs---2NC

The plan requires overwhelming, wrenching tax increases---more than it took to fight World War II---that sparks a massive public backlash because people don’t perceive employer-provided insurance as costing them anything, but they hate the shit out of new taxes

Jacob S. Hacker 18, the Stanley Resor Professor of Political Science at Yale University, 1/3/18, “The Road to Medicare for Everyone,”

Our nation’s distinctive policy trajectory has left us with a fragmented and exorbitantly expensive system. At the same time, however, that system all but guarantees that every reasonably well-insured group—whether workers with employee health plans or beneficiaries of Medicare—will be distrustful of change and hyper-sensitive to new costs, even if those costs merely replace hidden charges they’re now paying.

Remember: More than 150 million Americans are covered by employment-based health plans. These plans have become less common, more expensive, and more restrictive. Still, we’re talking half the population, and people with workplace coverage are generally satisfied (though beneficiaries of Medicare are even happier). Replacing these plans with Medicare would be a huge lift. Even the extremely modest dislocations caused by the ACA precipitated a bipartisan scramble to ensure people could keep their current plans, however ill-designed or inadequate.

2023 Northwestern Affirmative
Off › Part E CP › Solves Coverage---2NC

The counterplan is exactly like the plan for everyone who’s currently uninsured. Those are the only people that matter for coverage. And the CP provides better insurance than the plan for the 170 million people who get employer insurance. Single payer is a system shock that can only be worse for effective coverage

Tevi Troy 17, the Chief Executive Officer of the American Health Policy Institute and former Deputy Secretary of the U.S. Department of Health and Human Services, September 2017, “A Move to Single-Payer Health Care? Implications for Employer-Sponsored Care,”

Ultimately, whether America transitions to a single-payer system largely depends on a variety of factors: not just the short-term politics, but also how we get there from here, the period of transition, and ultimately the cost. Moving over 70 percent of the U.S. adult population, many of whom already receive better benefits via employer-sponsored care, to some kind of Medicare-for-All type system would be no small feat.8 Attempting to do this transition in a short period of time – just one year in a proposal by Michigan Representative John Conyers – could cause a serious shock to the health care system.9 Even a more gradual transition or moving to a system that is not entirely single-payer (perhaps allowing supplemental private insurance) raises many tough questions regarding both cost and logistics. Making a change to our health care system along single-payer lines will require extensive and detailed planning, since any one feature of the system or any one step of the process could have major repercussions for generations to come. It would also have to come to grips with resolving what to do with employer-sponsored care, which covers 61 percent of all Americans with health care benefits, the majority of whom are happy with their coverage.10

2023 Northwestern Affirmative
Off › Part E CP › Solves Coverage---2NC

The CP achieves 99.6% coverage while avoiding massive tax hikes and public backlash

Jacob S. Hacker 18, the Stanley Resor Professor of Political Science at Yale University, 1/3/18, “The Road to Medicare for Everyone,”

Of course, even with these savings, Medicare Part E would require additional financing beyond the employer contributions. For starters, those enrolled in Medicare Part E should have to pay an additional premium beyond the payroll-based contributions made by employers (or by self-employed workers). As in Medicare Part B, these premiums should cover only a modest fraction of the total cost of Medicare Part E, and they should vary by income, with lower-income enrollees paying a minimal amount. (For workers, these premiums should be automatically deducted from pay.) The exact premium would depend on the precise benefits covered, as well as the employer contribution rate. But the full charge for higher-income enrollees would likely be in the range of $300 per month for family coverage. This estimate is based on a 2008 analysis conducted by the Lewin Group—an independent consulting firm with expertise in micro-simulation modeling of health-care plans.

To be sure, other sources of financing would also be needed. The improved benefits for current Medicare beneficiaries could be financed, in part, by increasing the Medicare tax paid by workers (which the ACA applied, for the first time, to capital as well as labor income). There is also a strong argument for bridging some of the remaining funding gap with relatively progressive tax sources, such as an income-tax surcharge on extremely high-income households. Still, because most Americans who receive employment-based insurance will continue to do so, the new costs are much more modest than those for single-payer. In its 2008 analysis, Lewin estimated that 99.6 percent of Americans would be covered and that the proposal would lower national health spending and require modest new federal spending. Over time, it was projected to produce enormous savings for employers, households, states, and the federal government.

2023 Northwestern Affirmative
Off › Part E CP › Solves Costs---2NC

No solvency deficits---the CP creates the cost savings of single payer in a multi-payer system

Joshua Holland 17, fellow with The Nation Institute, 11/20/17, “Here’s a Path to Medicare for (Almost) All That Isn’t Doomed to Fail,”

There’s another way—one that’s national in scope but avoids the popular opposition that forcing a huge share of the population to give up their current insurance would elicit. It would also require significantly fewer tax dollars to work.

This missing path starts with the understanding that all of the goals of progressive health reform—universality, greater equity, an expansion of public health care, cost containment through efficiencies of scale and reducing the role of profit in health care—can be accomplished to a significant degree without dismantling the current system entirely.

2023 Northwestern Affirmative
Off › Part E CP › Solves Costs---2NC

The CP solves costs better than the plan---it uses the massive market power of a large government-run risk pool to negotiate down prices, and creates an incentive for private plans to negotiate prices even lower---we have empirics on our side because the most efficient Medicare Advantage private plans already deliver costs lower than Medicare rates

Jacob S. Hacker 18, the Stanley Resor Professor of Political Science at Yale University, 1/3/18, “The Road to Medicare for Everyone,”

In short, opening up Medicare to everyone would deliver what’s most inspiring about single-payer—health care as a basic right of citizenship. Yet it wouldn’t require replacing employment-based health insurance in one fell swoop. That’s because a large share of employers now providing health benefits would likely continue to do so.

After all, the penalty in the ACA is modest compared with the cost of benefits, but most larger employers still offer health insurance. Some might feel less compunction about paying the fee if it were a contribution rather than a penalty. Some might not want to upgrade their plans to match Medicare Part E. But previous estimates of play-or-pay plans suggest that at any contribution rate close to the House plan’s, most employers providing coverage would continue providing coverage.

2023 Northwestern Affirmative
Off › Part E CP › 1NC

The counterplan achieves the universality and cost savings of single payer while preserving employer-based insurance and Medicaid---that’s key to public acceptance and policy durability

Jacob S. Hacker 18, the Stanley Resor Professor of Political Science at Yale University, 1/3/18, “The Road to Medicare for Everyone,”

But Democrats should not make the opposite mistake either. A proposal must have a realistic path to enactment. But it also has to be ambitious enough to inspire supporters, and compelling and understandable enough to convince others to become supporters. It has to be grounded in policies that are popular and known to work—policies that can actually reach universal coverage and restrain health-care prices.

Perhaps most important, it has to be able to command support not just before it passes, but also afterward. If the troubled saga of the exchanges tells us anything, it’s that even the most technically sound policy will fall short if it does not generate and sustain pressure for continuing expansion and improvement. Successful policies do not just reflect the politically possible; they reshape it.

2023 Northwestern Affirmative
Off › States CP › 50-State Fiat Good---2NC

Education---understanding the role of federalism in healthcare is essential to policy discussion

Michael Doonan 13, assistant professor at the Heller Graduate School at Brandeis University, executive director of the Massachusetts Health Policy Forum and director of the Council for Health Care Economics and Policy, 8/29/13, "American Federalism in Practice, The Formulation and Implementation of Contemporary Health Policy," Brookings Institution Press, Chapter 1

Understanding how federalism—the division of power between the federal government and the states—plays out is essential to understanding contemporary health policy. The case studies presented here describe a dynamic intergovernmental relationship that varies dramatically depending on the political context in each case and the manner within each state in which rulemaking and implementation are conducted. Health policymaking is entangled in a complex web of shared, overlapping, and/or competing power relationships between levels of government.9 While traditional studies of federalism offer great insight into federal-state interactions, most do little to explain variations in interactions across the policy process. Understanding those variations is essential to understanding the ultimate impact of federalism on programs and policy.

2023 Northwestern Affirmative
Off › States CP › AT: ERISA Preemption---General

Courts will defer against ERISA preemption

Samuel Salganik 9, JD Candidate, Columbia Law School, “What the Unconstitutional Conditions Doctrine Can Teach Us About ERISA Preemption: Is It Possible to Consistently Identify “Coercive” Pay-or-Play Schemes?” Columbia Law Review, Volume 109, Number 6, October 2009, pp. 1482-1530

In New York State Conference of Blue Cross äf Blue Shield Plans v. Travelers Ins. Co.107 and California Division of Labor Standards Enforcement v. Dillingham Construction, N.A., Inc.,108 when faced with laws creating indi- rect economic influences on ERISA plans, the Court retreated from the literalist line of Shaw.109 Discussing Shaw, the Court noted that "if ‘relate to' were taken to extend to the furthest stretch of its interdeterminacy, then for all practical purposes preemption would never run its course, for '[r]eally, universally, relations stop nowhere.'"110 The Court similarly rejected "uncritical literalism"111 with respect to the "connection with" prong of the Shaw test: "For the same reasons that infinite relations can- not be the measure of pre-emption, neither can infinite connections."112 In place of the hard line drawn by Shaw, where a literal reading of the words "relate to" gave § 514(a) very strong preemptive force, Travelers and Dillingham produce a softer standard, instructing courts to "look in- stead to the objectives of the ERISA statute as a guide"113 to determine its preemptive scope.

Following this softened approach, laws which merely influence the decisions of plan administrators by altering the economic incentives they face - such as those at issue in Travelers and Dillingham - need not be preempted, so long as the influence is not too acute. In Travelers, the Court upheld a New York law that required hospitals to impose surcharges on patients covered by insurers other than Blue Cross & Blue Shield (“the Blues").114 While the law "ma[d]e the Blues more attractive . . . and thus ha[d] an indirect economic effect on choices made by insurance buy- ers,"115 the Court held that such an "indirect economic influence [did] not bind plan administrators to any particular choice and thus function as a regulation of an ERISA plan."116 Likewise, in Dillingham, the Court upheld a California law that produced an economic incentive for local apprenticeship programs to comply with state regulations in addition to ERISA.117 As in Travelers, a state law which "alter [ed] the incentives, but d[id] not dictate the choices, facing ERISA plans"118 was not preempted. Travelers and Dillingham therefore weakened the Shaw standard by saving from preemption state laws that merely influence the decisionmaking of ERISA plan managers.119